NCT01231841View on ClinicalTrials.gov

Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Aplastic Anemia
Interventions
DRUG

cyclosporine

Given orally

BIOLOGICAL

anti-thymocyte globulin

Given IV

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER

NCT01231841 - Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter